Biliary tract cancers, encompassing cancers of the gallbladder, extrahepatic bile ducts, and ampulla of Vater, are rare but highly fatal. Gallstones represent the major risk factor for biliary tract cancer, and share with gallbladder cancer a female predominance and an association with reproductive factors and obesity. Although estrogens have been implicated in earlier studies of gallbladder cancer, there are no data on the role of androgens. Because intracellular androgen activity is mediated through the androgen receptor (AR), we examined associations between AR CAG repeat length [(CAG)n] and the risk of biliary tract cancers and stones in a population-based study of 331 incident cancer cases, 837 gallstone cases, and 750 controls from Shanghai, China, where the incidence rates for biliary tract cancer are rising sharply. Men with (CAG)n >24 had a significant 2-fold risk of gallbladder cancer [odds ratio (OR), 2.00; 95% confidence interval (CI), 1.07-3.73], relative to those with (CAG)n ≤ 22. In contrast, women with (CAG)n >24 had reduced gallbladder cancer risk (OR, 0.69; 95% CI, 0.43-1.09) relative to those with (CAG)n ≤ 22; P interaction sex = 0.01, which was most pronounced for women ages 68 to 74 (OR, 0.48; 95% CI, 0.25-0.93; P interaction age = 0.02). No associations were found for bile duct cancer or gallstones. Reasons for the heterogeneity of genetic effects by gender and age are unclear but may reflect an interplay between AR and the levels of androgen as well as estrogen in men and older women. Further studies are needed to confirm these findings and clarify the mechanisms involved. Cancer Epidemiol Biomarkers Prev; 19(3); 787–93

Biliary tract cancers, encompassing cancers of the gallbladder, extrahepatic bile duct, and ampulla of Vater, are rare but highly fatal (1). Gallstones represent a major predisposing factor, especially for gallbladder cancer, the most common type of biliary cancer (1, 2). Gallstones and gallbladder cancer are twice as common in women as in men (1, 2), and it is thought that sex hormones, in particular estrogens, may explain part of their female excess (1). In females, both gallbladder cancer and gallstones have been linked to reproductive factors, including parity, age at menarche, and age at menopause, providing support for an etiologic role for estrogens (1). Bile duct cancers, which are slightly more common in men, seem more related to smoking and inflammatory processes (1, 2), and any hormonal involvement is unclear.

Intracellularly, sex hormone activity is mediated through the androgen receptor (AR) as well as the estrogen receptors (ESR1 and ESR2; ref. 3). We recently showed that variation in ESR1 and ESR2 genes is associated with cancers of the bile duct and ampulla of Vater,11

11S.K. Park, G. Andreotti, A. Rashid, et al. Polymorphisms of estrogen receptors and risk of biliary tract cancers and gallstones: a population-based study in Shanghai, China.

yet there are currently no reports on the association between biliary tract cancers and variation in the AR gene.

After binding androgen, the AR-hormone complex regulates the transcription of androgen-responsive genes (4). The AR gene, present on the X chromosome, contains a highly polymorphic CAG repeat that normally varies between 9 and 37 repeats in length (5). CAG length [(CAG)n] is inversely associated with the transcriptional activity of the AR such that having longer (CAG)n reduces the transcriptional activity of the AR and subsequent intracellular androgenic activity (5, 6). (CAG)n greater than ∼37 repeats in length is associated with pathologic conditions related to reduced androgenicity such as gynecomastia and ineffective spermatogenesis (5). Although AR CAGn has been associated with the risk of hormone-related cancers, such as breast and prostate cancers (7, 8), there is no data on (CAG)n and biliary tract cancers. In this report, we examined the association between (CAG)n and the risk of biliary tract cancers and stones in a population-based case-control study from Shanghai, China to further clarify the etiologic role of sex hormones on biliary tract cancers.

Study Population

Details of the study have been described elsewhere (9). Briefly, incident cancers were ascertained from 38 hospitals in Shanghai, China with >95% capture of cases during the study period. Cases were confirmed using histology and imaging results. Gallstone cases were frequency-matched to cancer cases on age, sex, and hospital and were confirmed using medical records, pathology reports, and imaging data. Subjects without cancer were randomly selected from the Shanghai Resident Registry and were frequency-matched to cases on age and sex. For this study, we included 331 incident cancer cases, 837 gallstone cases, and 750 controls. We excluded ampulla of Vater cancers due to small numbers (n = 41).

Data Collection

Information on demographic characteristics, smoking, drinking, medical history, and reproductive history was collected within 3 wk of case diagnosis. Trained nurses measured height and weight, and collected fasting blood samples. Participation was 95% for cases and 82% for controls. Within 3 mo of the primary interview, 5% of subjects were randomly selected for re-interview; reproducibility was >90%.

Genotyping

(CAG)n was chosen because of its known functional effect on AR transcriptional activity (6). For genotyping, we used an automated fragment analysis method described elsewhere (10, 11). Briefly, DNA samples were amplified by PCR before automated fragment analysis on an ABI Prism Model 310 Genetic Analyzer. Samples were run on a capillary containing POP-4 polymer and the data were analyzed with GeneScan analysis software, version 2.0.2. The accuracy of the automated fragment analysis method was shown by direct sequencing (11). In all quality control samples, sequencing confirmed the (CAG)n by automated fragment analysis. In this study, reproducibility across 20 aliquots of five samples was >90%.

Statistical Methods

Body mass index (kg/m2) was categorized using WHO classification for obesity in Asians. Age at menarche was categorized into tertiles based on the distribution among controls. Distributions of putative risk factors including age, sex, smoking, drinking, hypertension, diabetes, gallstones, and body mass index, as well as parity, menopausal status, and age at menarche among women by case-control status are presented in Supplementary Table S1.

Because one copy of the X chromosome is randomly inactivated in female cells such that women generally have a 50:50 expression of the paternal/maternal X chromosomes (12), we used the biallelic mean for (CAG)n in women. Distributions of (CAG)n allele frequencies by case status were plotted for men and women separately and overlaid with smoothed kernel densities. Tertiles of (CAG)n were defined based on the distribution among all controls (≤22, 23-24, >24). Odds ratios (OR) and 95% confidence intervals (CI) were estimated from unconditional logistic regression models minimally adjusted for age and sex and from models fully adjusted for risk factors (Supplementary Table S1). Linear trends in genetic effects across tertiles were evaluated using the Wald P for trend. Bile duct cancer cases were compared with all controls (n = 750), gallbladder cancer cases with controls without cholecystectomy (n = 704), and gallstone cases with controls without stones (n = 562). Heterogeneity of genetic effects by factors listed in Supplementary Table S1 was evaluated using the likelihood ratio test.

The mean (CAG)n in controls was 23.1 (range, 8-33), with a similar distribution among men and women. Among cases, the means of (CAG)n were 23.1, 23.5, and 23.2 for gallbladder cancer, bile duct cancer, and gallstones, respectively. Male gallbladder cancer cases and controls had a bimodal (CAG)n distribution (Fig. 1A), but there was no significant difference in mean or median (CAG)n (data not shown). In women, there was no difference in the continuous distribution of (CAG)n between cases and controls (Fig. 1B), but an inverse association of borderline significance was seen when (CAG)n was categorized as tertiles (P trend = 0.09; Table 1). Specifically, women with (CAG)n >24 had reduced gallbladder cancer risk (OR, 0.69; 95% CI, 0.43-1.09), relative to those with (CAG)n <23. In contrast, men with (CAG)n >24 had significantly increased gallbladder cancer risk (OR, 2.00; 95% CI, 1.07-3.73), relative to those with (CAG)n <23, and a significant linear trend (P trend = 0.04; Table 1). Heterogeneity of genetic effects by gender was statistically significant (P interaction = 0.01). There were no case-control differences in the distribution of (CAG)n for bile duct cancer or gallstones using (CAG)n as a continuous variable or in tertiles (Supplementary Figs. S1A-S2B; Table 1). Further adjustment for factors in Supplementary Table S1 did not materially change results (data not shown).

Figure 1.

A, distribution of AR CAG repeat allele frequencies by gallbladder cancer case-control status in men. One case with an extreme value of AR CAG repeat length 50 was excluded from the plot in males. Only controls without cholecystectomy are included. B, distribution of AR CAG repeat allele frequencies by gallbladder cancer case-control status in women. The biallelic mean AR (CAG)n is reported among women; only controls without cholecystectomy are included.

Figure 1.

A, distribution of AR CAG repeat allele frequencies by gallbladder cancer case-control status in men. One case with an extreme value of AR CAG repeat length 50 was excluded from the plot in males. Only controls without cholecystectomy are included. B, distribution of AR CAG repeat allele frequencies by gallbladder cancer case-control status in women. The biallelic mean AR (CAG)n is reported among women; only controls without cholecystectomy are included.

Close modal
Table 1.

OR and 95% CIs for biliary tract cancer and stones in relation to AR CAG repeat length

TotalAR (CAG)n <23*AR (CAG)n = 23-24*AR (CAG)n >24*P for trend
nnORnOR (95% CI)nOR (95% CI)
Men and women 
    Control set 1§ 750 288  260  202   
    Control set 2 704 269  240  195   
    Control set 3 562 211  192  159   
    Gallbladder cancer 215 90 Reference 59 0.68 (0.46-0.99) 66 0.99 (0.69-1.44) 0.83 
    Bile duct cancer 116 42 Reference 38 1.15 (0.71-1.85) 36 1.31 (0.81-2.14) 0.27 
    Gallstones 837 317 Reference 273 0.91 (0.70-1.18) 247 1.05 (0.80-1.38) 0.77 
Men 
    Control set 1§ 293 131  84  78   
    Control set 2 281 128  77  76   
    Control set 3 242 105  70  67   
    Gallbladder cancer 58 23 Reference 0.58 (0.25-1.37) 27 2.00 (1.07-3.73) 0.04 
    Bile duct cancer 70 30 Reference 20 1.04 (0.56-1.96) 20 1.13 (0.60-2.12) 0.72 
    Gallstones 313 130 Reference 80 0.92 (0.61-1.40) 103 1.26 (0.84-1.88) 0.30 
Women 
    Control set 1§ 457 157  176  124   
    Control set 2 423 141  163  119   
    Control set 3 320 106  122  92   
    Gallbladder cancer 157 67 Reference 51 0.66 (0.43-1.01) 39 0.69 (0.43-1.09) 0.09 
    Bile duct cancer 46 12 Reference 18 1.35 (0.63-2.89) 16 1.66 (0.75-3.64) 0.21 
    Gallstones 524 187 Reference 193 0.88 (0.63-1.23) 144 0.92 (0.64-1.32) 0.61 
TotalAR (CAG)n <23*AR (CAG)n = 23-24*AR (CAG)n >24*P for trend
nnORnOR (95% CI)nOR (95% CI)
Men and women 
    Control set 1§ 750 288  260  202   
    Control set 2 704 269  240  195   
    Control set 3 562 211  192  159   
    Gallbladder cancer 215 90 Reference 59 0.68 (0.46-0.99) 66 0.99 (0.69-1.44) 0.83 
    Bile duct cancer 116 42 Reference 38 1.15 (0.71-1.85) 36 1.31 (0.81-2.14) 0.27 
    Gallstones 837 317 Reference 273 0.91 (0.70-1.18) 247 1.05 (0.80-1.38) 0.77 
Men 
    Control set 1§ 293 131  84  78   
    Control set 2 281 128  77  76   
    Control set 3 242 105  70  67   
    Gallbladder cancer 58 23 Reference 0.58 (0.25-1.37) 27 2.00 (1.07-3.73) 0.04 
    Bile duct cancer 70 30 Reference 20 1.04 (0.56-1.96) 20 1.13 (0.60-2.12) 0.72 
    Gallstones 313 130 Reference 80 0.92 (0.61-1.40) 103 1.26 (0.84-1.88) 0.30 
Women 
    Control set 1§ 457 157  176  124   
    Control set 2 423 141  163  119   
    Control set 3 320 106  122  92   
    Gallbladder cancer 157 67 Reference 51 0.66 (0.43-1.01) 39 0.69 (0.43-1.09) 0.09 
    Bile duct cancer 46 12 Reference 18 1.35 (0.63-2.89) 16 1.66 (0.75-3.64) 0.21 
    Gallstones 524 187 Reference 193 0.88 (0.63-1.23) 144 0.92 (0.64-1.32) 0.61 

*AR (CAG)n tertiles based on the distribution among all controls for one allele in men and the mean of two alleles in women.

P for trend is based on a Wald test for the linear trend in effect across tertiles of AR (CAG)n.

Adjusted for age and sex.

§All controls used for comparison with bile duct cancer cases.

Controls without cholecystectomy used for comparison with gallbladder cancer cases.

Controls without gallstones used for comparison with gallstone cases.

We found a significant interaction between (CAG)n and tertiles of age in women (P interaction = 0.02) but not in men. The interaction between (CAG)n and age in women was also apparent using age modeled as quartiles (P interaction = 0.01) and as a continuous variable (P interaction = 0.10). There was an inverse association between (CAG)n and gallbladder cancer risk among women in the oldest age group (68-74 years; P trend = 0.02), but not in the younger age groups. Older women with (CAG)n >24 had a reduced risk of gallbladder cancer (OR, 0.48; 95% CI, 0.25-0.93) relative to those with (CAG)n <23 (Table 2). The age interaction persisted after adjustment for parity, body mass index, and menopausal status (data not shown). There were too few cases of gallbladder cancer among premenopausal women (n = 14) to test the potentially more biologically relevant interaction between menopausal status and tertiles of (CAG)n. However, the interaction between (CAG)n and age persisted in postmenopausal women (P interaction = 0.03 for tertiles of age). Heterogeneity of genetic effects by the other factors in Supplementary Table S1 was not statistically significant.

Table 2.

ORs and 95% CIs for gallbladder cancer in relation to AR CAG repeat length by tertiles of age in women

TotalAR (CAG)n <23*AR (CAG)n 23-24*AR (CAG)n >24*P for trend
nnORnOR (95% CI)nOR (95% CI)
Age, 34-61 
Controls 129 42  56  31   
Gallbladder cancer 40 15 Reference 14 0.70 (0.30-1.61) 11 0.99 (0.40-2.46) 0.92 
Age, 62-67 
Controls 125 51  45  29   
Gallbladder cancer 43 15 Reference 22 1.66 (0.77-3.59) 0.70 (0.25-2.01) 0.80 
Age, 68-74 
Controls 169 48  62  59   
Gallbladder cancer 74 37 Reference 15 0.31 (0.15-0.64) 22 0.48 (0.25-0.93) 0.02 
TotalAR (CAG)n <23*AR (CAG)n 23-24*AR (CAG)n >24*P for trend
nnORnOR (95% CI)nOR (95% CI)
Age, 34-61 
Controls 129 42  56  31   
Gallbladder cancer 40 15 Reference 14 0.70 (0.30-1.61) 11 0.99 (0.40-2.46) 0.92 
Age, 62-67 
Controls 125 51  45  29   
Gallbladder cancer 43 15 Reference 22 1.66 (0.77-3.59) 0.70 (0.25-2.01) 0.80 
Age, 68-74 
Controls 169 48  62  59   
Gallbladder cancer 74 37 Reference 15 0.31 (0.15-0.64) 22 0.48 (0.25-0.93) 0.02 

NOTE: P interaction for tertiles of AR (CAG)n and age for women were as follows: P = 0.10 for continuous age, P = 0.01 for quartiles of age, and P = 0.02 for tertiles of age. Results are shown for tertiles of age because the number of cases by (CAG)n tertiles within quartiles of age were too small for valid estimates.

*AR (CAG)n tertiles based on the distribution among all controls for one allele in men and the mean of two alleles in women.

P for trend is based on a Wald test for the linear trend in effect across tertiles of AR (CAG)n.

Population controls without cholecystectomy.

In this population-based study, we showed that longer AR (CAG)n is associated with increased gallbladder cancer risk in men but reduced risk in women, especially those at older ages. In contrast, no association was found between (CAG)n and bile duct cancer or gallstones.

Confounding by putative risk factors (Supplementary Table S1) is unlikely to explain our findings because adjustment did not materially change the effect. It is also unlikely that genotyping errors could explain our findings because the genotyping method used in the study was validated against sequencing results with good concordance (11). Furthermore, the (CAG)n distribution in our subjects was similar to the distribution in a previous study in Shanghai males using direct sequencing (13). Measurement of (CAG)n in women is more complex because only one copy of the AR is expressed (12), leading to a 50:50 paternal/maternal AR copy expression (14). Using the mean of two CAG repeats might not have captured the true expression of AR in women. Such measurement error, if any, would bias the association toward the null and would not explain the opposite effects in men and women. Furthermore, we saw a similar reduction in gallbladder cancer risk in older women across (CAG)n tertiles using the shorter or longer copy of (CAG)n (data not shown).

Given the known association between longer (CAG)n and reduced AR transcriptional activity (6), the lower risk associated with longer (CAG)n in women suggests that lower intracellular androgenic activity decreases gallbladder cancer risk in older women. Longer (CAG)n has been linked with lower testosterone levels in both premenopausal and postmenopausal women in some (15-17) but not all (18-20) studies. Lower testosterone levels have also been noted in women treated with AR antagonists (21-24). Together, these data suggest that androgenic activity may play a role in gallbladder cancer in women, although estrogens have long been implicated in the etiology of gallbladder cancer due to the higher rates in women and the association between gallbladder cancer and reproductive factors (1). The observation that (CAG)n is associated with gallbladder cancer risk in women does not seem to implicate estrogen directly because there does not seem to be a correlation between (CAG)n and estrogen levels in women (15, 17), and because the interaction between (CAG)n and age on gallbladder cancer risk persisted among postmenopausal women who generally have lower estrogen levels than men (25). However, because we do not have measurements of serum testosterone or estrogen levels in our study, it is difficult to tease out whether the observed association is related to reduced androgenic activity or the imbalance of estrogen and androgen.

The decreased gallbladder cancer risk associated with lower androgenic activity or imbalance of estrogen and androgen is biologically plausible because androgens are involved in regulating cell cycle control and differentiation in hormone-responsive tissues (26), which are likely to include the gallbladder (1). Furthermore, our recent finding that variants in the CYP19A1 gene, encoding aromatase that converts androgen to estrogen (27, 28), are associated with gallbladder cancer risk (29), further suggests that an imbalance of androgens and estrogens may be involved in gallbladder cancer.

In contrast with women, the positive association between gallbladder cancer risk and (CAG)n in men suggests that, in men, lower intracellular androgenic activity may increase the risk of gallbladder cancer. The divergent results in men and women may seem paradoxical at first, but is consistent with the apparent sex-specific differences in the relationship between (CAG)n and testosterone levels in men and women, and the hypothesis that androgen-estrogen imbalance may also have a role in gallbladder cancer pathogenesis. Contrary to the relationship in women, some (30-33), but not all (34-38) studies have shown that (CAG)n is positively correlated with levels of testosterone in men, and clinical studies show a clear increase in testosterone levels in men treated with AR antagonists (39). Currently, the positive correlation between (CAG)n and serum androgen levels is thought to be part of a feedback loop to compensate for lower AR-mediated androgenic activity in men with longer (CAG)n (refs. 30, 31). Although longer (CAG)n has been associated with increased estrogen levels in men in two studies (31, 34), most studies have not shown a correlation between estrogen levels and (CAG)n in men (30, 35, 37, 38). Thus, similar to the results in women, our results in men provide further support for a possible role of androgens in gallbladder cancer. However, a full understanding of the divergent direction of association between AR (CAG)n and risk of gallbladder cancer in men and women will require a prospective study with sufficient size and measurements of serum androgen and estrogen as well as their respective receptors to clarify the specific contribution of androgens, estrogen, and imbalance of estrogen and androgen in gallbladder cancer etiology.

Our null finding for bile duct cancer is not unexpected because risk is not as closely related to gallstones, reproductive factors, and obesity (1, 2). However, we found that ESR variation is associated with bile duct cancer in a previous report,11 so our null finding should be confirmed. The lack of association between (CAG)n and gallstones is surprising because gallstones are closely related to the pathogenesis of gallbladder cancer (1). This finding suggests that androgenic activity may contribute to gallbladder cancer risk through mechanisms independent of stones.

The strengths of this study include its relatively large size and the population-based design with validation procedures designed to minimize misclassification of exposure and outcome. Limitations are the case-control design and lack of information on circulating hormones, which is needed to understand the individual and combined effects of sex hormones and nuclear receptors.

In summary, our population-based case-control study showed that (CAG)n was positively associated with gallbladder cancer risk in men but inversely associated with gallbladder cancer in older women. The gender differences may reflect interactions between AR-influenced androgenic activity and circulating levels of sex hormones. The findings should inform prospective studies into the role of sex hormones and genetic modifiers in the etiology of biliary tract cancer and stones.

No potential conflicts of interest were disclosed.

We thank Jiarong Cheng, Lu Sun, Kai Wu, Enju Liu, and the staff at the Shanghai Cancer Institute for data collection, specimen collection, and processing; collaborating hospitals and surgeons for data collection; local pathologists for pathology review; Janis Koci at the Scientific Applications International Corporation for management of the biological samples; and Dr. B.J. Stone at the National Cancer Institute for expert editorial assistance.

Grant Support: Intramural Research Program of the NIH and National Cancer Institute, NIH under contract N01-CO-12400. The contents of this publication do not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1
Hsing
AW
,
Rashid
A
,
Devesa
SS
,
Fraumeni
JF
 Jr
. 
Biliary tract cancer
. In:
Schottenfeld
D
,
Fraumeni
JF
 Jr.
, editors.
Cancer epidemiology and prevention
. 3rd ed.
New York
:
Oxford University Press
; 
2006
, p.
787
800
.
2
Khan
ZR
,
Neugut
AI
,
Ahsan
H
,
Chabot
JA
. 
Risk factors for biliary tract cancers
.
Am J Gastroenterol
1999
;
94
:
149
52
.
3
Beato
M
,
Klug
J
. 
Steroid hormone receptors: an update
.
Hum Reprod Update
2000
;
6
:
225
36
.
4
Wierman
ME
. 
Sex steroid effects at target tissues: mechanisms of action
.
Adv Physiol Educ
2007
;
31
:
26
33
.
5
Zitzmann
M
,
Nieschlag
E
. 
The CAG repeat polymorphism within the androgen receptor gene and maleness
.
Int J Androl
2003
;
26
:
76
83
.
6
Chamberlain
NL
,
Driver
ED
,
Miesfeld
RL
. 
The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function
.
Nucleic Acids Res
1994
;
22
:
3181
6
.
7
Nelson
KA
,
Witte
JS
. 
Androgen receptor CAG repeats and prostate cancer
.
Am J Epidemiol
2002
;
155
:
883
90
.
8
Lillie
E
,
Bernstein
L
,
Ursin
G
. 
The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer
.
Breast Cancer Res
2003
;
5
:
164
73
.
9
Hsing
AW
,
Sakoda
LC
,
Rashid
A
, et al
. 
Variants in inflammation genes and the risk of biliary tract cancers and stones: a population-based study in China
.
Cancer Res
2008
;
68
:
6442
52
.
10
Boorman
DW
,
Guo
Y
,
Visvanathan
K
,
Helzlsouer
K
,
O'Brien
TG
. 
Automated fragment analysis method for determining androgen receptor CAG repeat length
.
Biotechniques
2002
;
33
:
140
3
.
11
O'Brien
TG
,
Guo
Y
,
Visvanathan
K
, et al
. 
Differences in ornithine decarboxylase and androgen receptor allele frequencies among ethnic groups
.
Mol Carcinog
2004
;
41
:
120
3
.
12
Lyon
MF
. 
X-chromosome inactivation
.
Curr Biol
1999
;
9
:
R235
7
.
13
Hsing
AW
,
Gao
Y-T
,
Wu
G
, et al
. 
Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China
.
Cancer Res
2000
;
60
:
5111
6
.
14
Kristiansen
M
,
Knudsen
GPS
,
Bathum
L
, et al
. 
Twin study of genetic and aging effects on X chromosome inactivation
.
Eur J Hum Genet
2005
;
13
:
599
606
.
15
Brum
IS
,
Spritzer
PM
,
Paris
F
,
Maturana
MA
,
Audran
F
,
Sultan
C
. 
Association between androgen receptor gene CAG repeat polymorphism and plasma testosterone levels in postmenopausal women
.
J Soc Gynecol Investig
2005
;
12
:
135
41
.
16
Ibanez
L
,
Ong
KK
,
Mongan
N
, et al
. 
Androgen receptor gene CAG repeat polymorphism in the development of ovarian hyperandrogenism
.
J Clin Endocrinol Metab
2003
;
88
:
3333
8
.
17
Westberg
L
,
Baghaei
F
,
Rosmond
R
, et al
. 
Polymorphisms of the androgen receptor gene and the estrogen receptor {β} gene are associated with androgen levels in women
.
J Clin Endocrinol Metab
2001
;
86
:
2562
8
.
18
Haiman
CA
,
Brown
M
,
Hankinson
SE
, et al
. 
The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study
.
Cancer Res
2002
;
62
:
1045
9
.
19
Hickey
T
,
Chandy
A
,
Norman
RJ
. 
TheaAndrogen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian Caucasian women with infertility related to polycystic ovary syndrome
.
J Clin Endocrinol Metab
2002
;
87
:
161
5
.
20
Hietala
M
,
Sandberg
T
,
Borg
A
,
Olsson
H
,
Jernstrom
H
. 
Testosterone levels in relation to oral contraceptive use and the androgen receptor CAG and GGC length polymorphisms in healthy young women
.
Hum Reprod
2007
;
22
:
83
91
.
21
Ibanez
L
,
Potau
N
,
Marcos
MV
,
de Zegher
F
. 
Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide
.
J Clin Endocrinol Metab
2000
;
85
:
3251
5
.
22
Leo
VD
,
Lanzetta
D
,
Cariello
PL
,
D'Antona
D
,
Morgante
G
. 
Effects of flutamide on pituitary and adrenal responsiveness to corticotrophin releasing factor (CRF)
.
Clin Endocrinol
1998
;
49
:
85
9
.
23
Moghetti
P
,
Casterllo
R
,
Negri
C
, et al
. 
Flutamide in the treatment of hirsutism: long-term clinical effects, endocrine changes, and androgen receptor behavior
.
Fertil Steril
1995
;
64
:
511
7
.
24
Venturoli
S
,
Marescalchi
O
,
Colombo
FM
, et al
. 
A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism
.
J Clin Endocrinol Metab
1999
;
84
:
1304
10
.
25
Greendale
GA
,
Edelstein
S
,
Barrett-Connor
E
. 
Endogenous sex steroids and bone mineral density in older women and men: The Rancho Bernardo Study
.
J Bone Mineral Res
1997
;
12
:
1833
43
.
26
Ferro
P
,
Catalano
MG
,
Dell'Eva
R
,
Fortunati
N
,
Pfeffer
U
. 
The androgen receptor CAG repeat: a modifier of carcinogenesis?
Mol Cell Endocrinol
2002
;
193
:
109
20
.
27
Kamat
A
,
Hinshelwood
MM
,
Murry
BA
,
Mendelson
CR
. 
Mechanisms in tissue-specific regulation of estrogen biosynthesis in humans
.
Trends Endocrinol Metab
2002
;
13
:
122
8
.
28
Schwarz
D
,
Kisselev
P
,
Schunck
W-H
, et al
. 
Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity
.
Pharmacogenet Genomics
2000
;
10
:
519
30
.
29
Park
SK
,
Andreotti
G
,
Sakoda
LC
, et al
. 
Variants in hormone-related genes and the risk of biliary tract cancers and stones: a population-based study in China
.
Carcinogenesis
2009
;
30
:
606
14
.
30
Crabbe
P
,
Bogaert
V
,
De Bacquer
D
,
Goemaere
S
,
Zmierczak
H
,
Kaufman
JM
. 
Part of the interindividual variation in serum testosterone levels in healthy men reflects differences in androgen sensitivity and feedback set point: contribution of the androgen receptor polyglutamine tract polymorphism
.
J Clin Endocrinol Metab
2007
;
92
:
3604
10
.
31
Huhtaniemi
IT
,
Pye
SR
,
Limer
KL
, et al
. 
Increased estrogen rather than decreased androgen action Is associated with longer androgen receptor CAG repeats
.
J Clin Endocrinol Metab
2009
;
94
:
277
84
.
32
Mifsud
A
,
Choon
AT
,
Fang
D
,
Yong
EL
. 
Prostate-specific antigen, testosterone, sex-hormone binding globulin and androgen receptor CAG repeat polymorphisms in subfertile and normal men
.
Mol Hum Reprod
2001
;
7
:
1007
13
.
33
Walsh
S
,
Zmuda
JM
,
Cauley
JA
, et al
. 
Androgen receptor CAG repeat polymorphism is associated with fat-free mass in men
.
J Appl Physiol
2005
;
98
:
132
7
.
34
Alevizaki
M
,
Cimponeriu
AT
,
Garofallaki
M
, et al
. 
The androgen receptor gene CAG polymorphism is associated with the severity of coronary artery disease in men
.
Clin Endocrinol
2003
;
59
:
749
55
.
35
Goutou
M
,
Sakka
C
,
Stakias
N
,
Stefanidis
I
,
Koukoulis
GN
. 
AR CAG repeat length is not associated with serum gonadal steroids and lipid levels in healthy men
.
Int J Androl
2009
;
32
:
616
22
.
36
Lapauw
B
,
Goemaere
S
,
Crabbe
P
,
Kaufman
JM
,
Ruige
JB
. 
Is the effect of testosterone on body composition modulated by the androgen receptor gene CAG repeat polymorphism in elderly men?
Eur J Endocrinol
2007
;
156
:
395
401
.
37
Van Pottelbergh
I
,
Lumbroso
S
,
Goemaere
S
,
Sultan
C
,
Kaufman
JM
. 
Lack of influence of the androgen receptor gene CAG-repeat polymorphism on sex steroid status and bone metabolism in elderly men
.
Clin Endocrinol
2001
;
55
:
659
66
.
38
Zitzmann
M
,
Brune
M
,
Kornmann
B
, et al
. 
The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity
.
J Clin Endocrinol Metab
2001
;
86
:
4867
73
.
39
Brufsky
A
,
Fontaine-Rothe
P
,
Berlane
K
, et al
. 
Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate
.
Urology
1997
;
49
:
913
20
.